Physician profile
Natalie Hunt Locklear
NPI 1326509472
$2,520.85
in general payments reported to CMS, 2019-2025
24 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $715 · 2023: $803 · 2024: $172 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,034.45 | 2021-2024 | |
| Ardelyx, INC. | $308.20 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $248.66 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $141.76 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $115.10 | 2022-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $84.58 | 2021-2022 | |
| Horizon Therapeutics Plc | $67.44 | 2021-2022 | |
| Exact Sciences Corporation | $56.45 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $55.96 | 2021-2023 | |
| Forte Bio-Pharma LLC | $48.56 | 2022-2023 | Prolate, Nalocet |
| Ironwood Pharmaceuticals, INC | $46.89 | 2024 | |
| Daiichi Sankyo INC. | $42.75 | 2021-2023 | Injectafer |
| Arbor Pharmaceuticals, INC. | $40.90 | 2022 | |
| Corcept Therapeutics | $32.96 | 2023-2024 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.33 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $32.27 | 2023 | Xarelto |
| Jazz Pharmaceuticals INC. | $26.96 | 2021 | |
| Shield Therapeutics INC | $16.38 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.14 | 2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $14.69 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.89 | 2023 | Nuedexta |
| Cequr Corporation | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.